and type IIB vWD, in both of which ristocetin-induced aggregation is known to be heightened. Aggregation induced by low shear stress was enhanced in both types of disorders compared to normal controls, and the enhancement was completely abolished by anti-vWF monoclonal antibody NMC4, which blocks the GPIb-binding site on vWF. Under high shear stress, the extent of maximal aggregation was not different between controls and the patient groups although maximal aggregation was reached much more quickly in the latter. When citrated PRP was exposed to a gradient of shear stress (6 to 108 dyn/cm2 over a 5-min period), vWF-dependent aggregation, as judged from the inhibitory effect of NMC4, first occurred at 14 dyn/cm2 in platelet-type vWD and at 10-12 dyn/cm2 in type IIB vWD, as compared with more than 81±20.1 dyn/cm2 in control platelets. These results suggest that an abnormality in either vWF or GPIb-IX triggers the aggregation-inducing interaction of the two molecules under low shear stress, which might explain the intravascular platelet
Introduction
An initial step in thrombogenesis involves the activation of platelets by their adherence to altered vascular endothelium or exposed subendothelial tissues through distinct platelet receptors and their ligands, followed by aggregation of incoming platelets to the adherent ones. Among various molecules involved in those events, vWF is a cornerstone of adhesive ligands, which, through interaction with its platelet receptor, GPIb-IX complex, can trigger platelet responses leading to the expression of receptor function of GPIIb-IIIa, another binding site for vWF on the platelet surface ( 1-3). Thus, vWF binding to GPIb-IX complex appears to play a crucial role in thrombus formation.
vWF in solution does not bind to resting, nonactivated platelets. An alteration either in the ligand or in the receptor is required for the interaction to occur (4) . vWF molecules that are known to interact with GPIb-IX complex include asialo vWF, vWF complexed with botrocetin, and insoluble surfacebound vWF (5) . Ristocetin is also well known to induce binding of vWF to GPIb-IX complex, although the mechanism remains to be understood.
Type IIB von Willebrand disease (vWD)' is an inherited bleeding disorder characterized by lack of larger multimers of plasma vWF and occasional thrombocytopenia (6, 7) . It is believed that abnormal plasma vWF interacts with GPIb-IX complex in vivo, resulting in intravascular platelet clumping and consumption of platelets. Conversely, an aberrant GPIb-IX receptor has been reported in pseudo-or platelet-type vWD, in which the receptor is always accessible to native vWF or "active," and the phenotype is thus similar to type IIB vWD (8, 9) . In both disorders the enhanced platelet aggregation induced by low concentrations of ristocetin is an in vitro feature; the exact mechanisms by which vWF binds to GPIb-IX complex, and how platelets are activated in vivo, remain to be clarified.
Under the high shear rate flow conditions normally found in the capillary microcirculation, vWF facilitates platelet adhe-sion to subendothelium by binding to GPIb-IX complex. Platelet aggregation, i.e., platelet-platelet contacts in suspension, can be triggered by shear stress even in the absence of agonists (1O). This shear-induced platelet aggregation (SIPA) is apparently vWF-dependent under high shear rate conditions. Using a novel mechanical device for continuous recording of SIPA, we have recently shown that different adhesive proteins and platelet membrane glycoproteins are involved in SIPA when tested in citrated PRP, depending on the shear stress conditions; platelet aggregation induced by low shear forces is mediated by fibrinogen binding to GPIIb-IIIa complex, whereas aggregation induced by high shear force is observed only when vWF is present and able to interact with both GPIb-IX and GPIIb-IIIa (1). Thus, vWF in the absence of exogenous agonists can mediate platelet aggregation in experimental conditions, which may mimic the hemorrheological situation ofpartially occluded arteries.
These observations prompted us to investigate the effects of various shear forces on SIPA in patients with type IIB-or platelet-type vWD. We found that, in both hereditary disorders showing heightened ristocetin-induced aggregation, vWF-dependent SIPA can be initiated even under the low shear stress normally generated in large vessels in vivo. The results might explain the molecular mechanisms of intravascular platelet clumping, which is thought to underlie the thrombocytopenia seen in both of these disorders.
Methods
Patients. Two patients with type IIB vWD in a single family, and one patient with platelet-type vWD have been characterized and reported in detail (9, 1 1). Both patients with type IIB vWD showed prolonged bleeding time, decreased ristocetin cofactor activity, and lack of larger multimers of plasma vWF. Platelet aggregation induced by low concentrations of ristocetin (0.4-0.8 mg/ml) was enhanced, and thrombocytopenia was observed after infusion of l-deamino-8-D-arginine vasopressin (DDAVP). In addition to the abnormal laboratory findings shown above, the patient with platelet-type vWD had moderate thrombocytopenia at the time of diagnosis and a high percentage of large platelets, as compared to normal individuals.
SIPA assay. The procedures to measure SIPA have been described in detail (1) . The anticoagulant used for blood collection was trisodium citrate at a final concentration of 0.01 1 M. Platelet-rich plasma (PRP) was prepared as described ( 1) . Platelet count was adjusted to 3 X lO5/gl for experiments with type IIB vWD and to 1.6 X 105/,Al for experiments with platelet-type vWD, using autologous platelet-poor plasma. The modified cone-and-plate-type viscometer was used for continuous measurement of SIPA. In one series of experiments, PRP was exposed to either low ( 18 dyn/cm2) or high ( 108 dyn/ cm2) constant shear stress for 5 min. In other experiments, a gradient of shear stress (6-108 dyn/cm2) was applied to PRP. After an initial 15 s at 6 dyn/ cm2, shear stress was increased to 12 dyn/cm2 in a 90-s period, was varied between 12 and 108 dyn/cm2 in the next 120 s, and was finally kept constant at 108 dyn/cm2 in the last 90 s.
Monoclonal antibody. Mouse monoclonal antibody NMC-4 has been described in detail (12) . NMC-4 recognizes the GPIb-binding domain of vWF and inhibits both ristocetin-and botrocetin-induced vWF binding to GPIb-IX complex.
Results
The effect of shear stress on platelet aggregation was examined, using citrated (Fig. 2) , showing that aggregation is vWF-dependent. PRP samples were then exposed to a gradient ofshear stress (6-108 dyn/cm2) over a 5-min period. After an initial 15-s period at 6 dyn/cm2, the intensity of shear stress was increased from 6 to 12 dyn/cm2 in a 90-s period, followed by an increase from 12 to 108 dyn/cm2 in 120 s, and then shear stress was kept constant at 108 dyn/cm2 for 90 s as shown by the broken line in Fig. 3 . In control platelets from a normal individual, a slight increase in light transmittance corresponding to the formation of platelet aggregates was seen under the shear stress between 6 and 12 dyn /cm2, as previously observed ( 1 ). In the ensuing 120 s, light transmittance decreased to near baseline, followed by a pronounced second increase. Analysis of 51 samples from healthy volunteers indicated that the light transmittance returned to baseline values at shear stress levels of 68±22.1 dyn/cm2 (mean±2SD) and second increase in light transmittance started at shear stress levels of 81±20.1 dyn/ 2 cm . In contrast, the aggregation curves in patients with type IIB and platelet-type vWD were totally different (Fig. 3 ). An initial increase in light transmittance induced by low shear stress was soon followed by much more pronounced increase in light transmittance. Prominent aggregations were first ob- (2, 14, 15) . It should be noted, however, that our device does not measure the amount of vWF bound on platelets but can measure the extent ofplatelet aggregation caused by vWF-platelet interaction.
The molecular basis of platelet-type-and type IIB vWD is not fully understood: however, we have described a point mutation in the gene encoding the a chain of GPIb in the present case ( 16) , and the same mutation has been reported in a different family with platelet-type vWD ( 17) . The ( 19) . One can speculate that the receptor is conformationally altered due to an amino acid substitution and is more sensitive to mechanical forces so that the "active" form ofthe receptor is readily achieved at low shear stress resulting in vWF binding. Similar speculation can be made for type IIB vWD, in which the molecular mechanisms of the disease have been investigated extensively in the past several years (7, (20) (21) (22) (23) (24) . In the two type IIB vWD patients of a single family presented here, a point mutation at residue 578 (Arg to Gln) of the vWF molecule was identified and assumed to be responsible for the abnormal vWF molecules, i.e., the higher affinity for GPIb-IX in the presence of low concentrations ofristocetin (25). It may be that abnormal vWF recog- platelets/,gl from a normal individual (N) and one patient with type IIB vWD (P) were exposed to a gradient of shear stress (6-108 dyn/ cm2) either in the presence or absence of monoclonal anti-vWF antibody NMC-4 at 12 ,ug/ml. Only one representative tracing was shown for the patients with type IIB vWD. Platelet-type vWD (right).
Citrated PRP containing 1.6 x 105 platelets/,pl from a normal individual (N) and the patient with platelet-type vWD (P) were exposed to a gradient of shear stress (6-108 dyn/cm2), either in the presence or absence of monoclonal anti-vWF antibody NMC-4. Broken lines indicate the change in the level of shear stress (see Methods). which is assumed to occur in vivo in both types ofpatients, and may give some insight into the mechanisms of the interaction between vWF and GPIb-IX receptor, which is one of the key steps in the regulation of thrombogenesis.
